Encysive Pharmaceuticals has hired an investment banking firm to help it evaluate strategic alternatives in the wake of a drug failure. Encysive already has said it will cut its U.S. work force by about 70% in response to the FDA's refusal in June to approve its Thelin hypertension drug.

Related Summaries